Lipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Lipocine (NASDAQ:LPCN) in a research note issued to investors on Tuesday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners began coverage on shares of Lipocine in a research note on Tuesday, September 24th. They set a “buy” rating and a $10.00 price objective on the stock.

Lipocine Price Performance

LPCN opened at $4.90 on Tuesday. Lipocine has a fifty-two week low of $2.44 and a fifty-two week high of $11.79. The business has a 50-day moving average of $5.14 and a 200-day moving average of $5.41. The company has a market capitalization of $26.22 million, a PE ratio of -6.45 and a beta of 1.24.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter. On average, equities research analysts expect that Lipocine will post -0.78 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lipocine

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP acquired a new stake in Lipocine Inc. (NASDAQ:LPCN) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned approximately 0.22% of Lipocine as of its most recent SEC filing. 9.11% of the stock is owned by institutional investors and hedge funds.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.